Skip Navigation LinksHome > March 2004 - Volume 43 - Issue 3 > Fenofibrate Increases Homocystinemia Through a PPARα-Mediate...
Journal of Cardiovascular Pharmacology:
Original Article

Fenofibrate Increases Homocystinemia Through a PPARα-Mediated Mechanism

Luc, Gérald MD*; Jacob, Nelly MD†; Bouly, Muriel PhD*; Fruchart, Jean-Charles PhD*; Staels, Bart PhD*; Giral, Philippe PhD‡

Free Access
Article Outline
Collapse Box

Author Information

From the *Department of Atherosclerosis, Institute Pasteur of Lille, France and Faculté de Pharmacie, University Lille II, France; †Laboratoire de Biochimie C, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; and ‡Service d'Endocrinologie-Métabolisme, Hôpital de la Pitié, Paris, France.

Received for publication September 6, 2003; accepted December 8, 2003.

Reprints: Gérald Luc, Department of Atherosclerosis, Insert U545, Institute Pasteur of Lille, France and Faculté de Pharmacie, University Lille II, France (e-mail: Gerald.Luc@pasteur-lille.fr).

Collapse Box

Abstract

Plasma homocysteine levels increase in humans treated with fibrates but the molecular mechanisms are unknown. The goal of the present study was to determine the mechanism of this increase using animal models. Firstly, an increase in homocysteine was observed in mice treated with fenofibrate irrespective of the genetic background C57BL/6 or SV129. Secondly, as the effect of fenofibrate on gene expression is mediated through activation of the peroxisome proliferator-activated receptor alpha (PPARα), a transcription factor belonging to the nuclear receptor family, it was determined whether the effect of fenofibrate on homocysteine levels were modulated through PPARα activation. Using PPARα-deficient mice, it was shown that the homocysteine increase after fenofibrate treatment was completely abolished in these animals. It can be concluded that fibrates increase homocystinemia through a PPARα-mediated mechanism and that mice constitute an animal model for analyzing the molecular mechanisms behind the homocysteine increase after fibrate therapy in dyslipidemic patients.

Fibrates constitute a class of frequently used normolipidemic drugs that effectively decrease triglyceride-rich lipoprotein and low-density lipoprotein and increase high-density lipoprotein (HDL) plasma levels in humans. They exert their effects, at least in part, through alterations in the transcription of genes encoding for proteins that control lipoprotein metabolism. 1 Indeed, fibrates activate specific transcription factors termed peroxisome proliferator-activated receptors (PPARs), a subfamily of nuclear receptors. 2 Particularly, the PPARα form mediates fibrate action on a number of genes involved in lipoprotein metabolism, fatty acid metabolism, and inflammation in the vascular wall. 1

Homocysteine is an intermediate compound formed during metabolism of methionine. It depends on a number of enzymes involved in the methionine cycle, folate cycle, and transsulfuration pathway. Folic acid, vitamin B6, and vitamin B12 serve as cofactors for a number of these enzymes. 3

Besides the effect on lipids, fenofibrate and bezafibrate were reported to increase plasma homocysteine concentrations in dyslipidemic patients in non-randomized, non-controlled clinical trials. 4–7 Among fibrates, only gemfibrozil has been demonstrated to increase homocysteine levels in a randomized controlled trial. 8 The mechanism of homocysteine increase in patients treated with fibrates remains to be established. Since fibrates induce the expression of several genes through PPARα activation, the aim of the present study was to investigate the role of PPARα in the fenofibrate-induced increase in homocysteine levels. To this end, we studied PPARα wild type (PPARα +/+) and homozygous-deficient mice (PPARα −/−).

Back to Top | Article Outline

MATERIALS AND METHODS

Mice used in this study were non-transgenic C57BL/6 mice, homozygous PPARα deficient mice (PPARα −/−), 9 and their wild type controls (PPARα+/+). PPARα−/− mice were obtained by disrupting the ligand-binding domain of the PPARα by homologous recombination. 9 PPARα−/− and PPARα+/+ mice had the SV129 genetic background; 10- to 16-week-old mice were caged in an animal room with an alternating 12-hour light (7 am to 7 pm) and dark (7 pm to 7 am) cycle. Every group of mice was equally subdivided and fed either the control or fenofibrate (0.2% wt/wt) mixed in chow diet ad libitum for 2 weeks. Body weight and food intake of the mice were regularly checked during the treatment period. No toxic side effect of fenofibrate treatment as checked by body weight changes was observed. Blood was taken from the retroorbital plexus from mice after a 2-hour fast. Plasma was immediately separated by centrifugation at 3000 rpm for 15 minutes, then frozen at −80°C until analysis. Plasma thiols were reduced by tri-n-butylphosphine, then derivated with sulfhydryl 7-fluoro-2,1,3-benzoxadialzole-4-sulfonamide. Total homocysteine was determined by high-performance liquid chromatography and fluorescence detection, as previously described. 10 The coefficient of variation of homocysteine levels was 5.5%.

Back to Top | Article Outline

RESULTS

Effect of Fenofibrate in C57BL/6 Mice

In a first experiment, it was evaluated whether mice increase plasma homocysteine levels when treated with fenofibrate in a manner similar to humans. Therefore animals (n = 5) were treated with fenofibrate mixed in diet (0.2%, wt/wt) while a similar group of animals were fed with chow diet. Fenofibrate treatment increased homocysteine levels from 7.6 ± 0.9 μmol/L in nontreated mice to 15.0 ± 3.1 μmol/L in mice treated with fenofibrate. This difference was significant (P < 0.01). Thus, as in humans, fenofibrate treatment increased homocysteine levels in C57BL/6 mice.

Back to Top | Article Outline
Effect of Fenofibrate in PPARα-Deficient Mice

To determine whether fenofibrate increased homocysteine through PPARα activation, mice deficient in PPARα and their wild type littermates were treated with fenofibrate 0.2%. Results are presented in Table 1. Fenofibrate significantly increased homocysteine in PPARα+/+ mice by 2.5-fold (ie, to the same extent as in C57BL/6 mice) whereas no significant changes were observed in PPARα−/− mice. Thus, fenofibrate exerts its effect on homocysteine levels via PPARα.

Table 1
Table 1
Image Tools
Back to Top | Article Outline

DISCUSSION

Since fibrate therapy in humans increases plasma homocysteine, the objective of this study was to examine if this increase is mediated by PPARα activation. Therefore, different mice were studied. In the first experiment, it was shown that, as in humans, fenofibrate treatment increased plasma homocysteine levels in wild type mice. The increase in homocysteine was observed in mice with 2 different genetic backgrounds. Secondly, this increase did not occur in PPARα-deficient mice. It can be concluded that fenofibrate increases homocysteine through PPARα activation. Several molecular mechanisms may lie at the basis of these effects. In humans, clinical studies suggest that fibrates such as fenofibrate and bezafibrate increase homocysteine, cysteine, and creatinine plasma levels. 4,7,10 Furthermore, it has been demonstrated that the increase in creatinine was not the consequence of a decrease in the glomerular filtration rate. 11 These findings therefore suggest that one or several enzymes involved in the metabolism of these substrates are modulated by fibrate treatment. A key enzyme common to the metabolism of these substrates is S-adenosyl transferase whose increase in activity could explain the metabolic findings. Therefore, a hypothesis is that PPARα increases the expression of methionine-adenosyl transferase, which transforms methionine into S-adenosyl methionine. However, as several enzymes contribute to the synthesis and catabolism of homocysteine, it is plausible that one or several enzymes involved in homocysteine synthesis are regulated by PPARα activation and/or that other enzymes metabolizing homocysteine to cystathionine or back to methionine are repressed. Just as for genes modulated by the PPARα pathway, it appears likely that the promoters of these genes may contain a functional PPRE.

Alternatively, as folic acid, vitamin B6, and vitamin B12 are importantly involved in homocysteine metabolism, it could be possible that fibrates modify the vitamin status in mice, although this hypothesis has been excluded in humans. 4

In conclusion, our results show that the homocysteine level increases in mice treated with fenofibrate; this effect is mediated by PPARα. Thus, mice are an excellent model to analyze the molecular mechanism of the homocysteine increase after fibrate therapy in dyslipidemic patients.

Back to Top | Article Outline

ACKNOWLEDGMENTS

The authors gratefully acknowledge Frank J. Gonzales, Laboratory of Metabolism, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA for obtaining PPARα-deficient mice.

Back to Top | Article Outline

REFERENCES

1. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999; 10:245–257.

2. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98:2088–2093.

3. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw Hill; 1989: 693–734.

4. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999; 354:219–220.

5. Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet. 2001; 358:39–40.

6. de Lorgeril M, Salen P, Paillard F, et al. Lipid-lowering drugs and homocysteine. Lancet. 1999; 353:209–210.

7. Giral P, Bruckert E, Jacob N, et al. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis. 2001; 154:421–427.

8. Schaefer EJ, Mcnamara JR, Selhub J, et al. Gemfibrozil treatment raised homocysteine concentrations in VA-HIT. Circulation. 2000; 102:II847.

9. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995; 15:3012–3022.

10. Jacob N, Bruckert E, Giral P, et al. Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis. 1999; 146:53–59.

11. Hottelart C, el Esper N, Achard JM, et al. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie. 1999; 20:41–44.

Cited By:

This article has been cited 16 time(s).

Nutrition
Elderly women: Homocysteine reduction by short-term folic acid supplementation resulting in increased glucose concentrations and affecting lipid metabolism (C677T MTHFR polymorphism)
Chmurzynska, A; Malinowska, AM; Twardowska-Rajewska, J; Gawecki, J
Nutrition, 29(6): 841-844.
10.1016/j.nut.2012.09.015
CrossRef
Lipids in Health and Disease
Plasma folate, but not homocysteine, is associated with Apolipoprotein A1 levels in a non-fortified population
Soderstrom, E; Eliasson, M; Johnson, O; Hallmans, G; Weinehall, L; Jansson, JH; Hultdin, J
Lipids in Health and Disease, 12(): -.
ARTN 74
CrossRef
Expert Opinion on Therapeutic Patents
Existing and potential therapeutic approaches targeting peroxisome proliferator-activated receptors in the management of Type 2 diabetes
Stefanski, A; Majkowska, L
Expert Opinion on Therapeutic Patents, 16(): 1713-1733.
10.1517/13543776.16.12.1713
CrossRef
Clinica Chimica Acta
Fenofibrate inhibits thrombogenic and fibrinolytic factors. expression in adipose tissue of atherosclerotic rabbits
Zhao, SP; Li, JQ; Xu, ZM; Wu, H; Li, QZ; Ye, HJ
Clinica Chimica Acta, 349(): 81-86.
10.1016/j.cccn.2004.06.004
CrossRef
American Journal of Cardiology
Safety considerations with fibrate therapy
Davidson, MH; Armani, A; McKenney, JM; Jacobson, TA
American Journal of Cardiology, 99(): 3C-18C.
10.1016/j.amjcard.2006.11.016
CrossRef
American Journal of Cardiology
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus
Terra, SG; Francone, OL; Contant, CF; Gao, X; Lewin, AJ; Nguyen, TT
American Journal of Cardiology, 102(4): 434-439.
10.1016/j.amjcard.2008.03.076
CrossRef
Nature Clinical Practice Cardiovascular Medicine
Fibrates and future PPAR alpha agonists in the treatment of cardiovascular disease
Staels, B; Maes, M; Zambon, A
Nature Clinical Practice Cardiovascular Medicine, 5(9): 542-553.
10.1038/ncpcardio1278
CrossRef
Journal of the American College of Cardiology
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha- dependent manner in vitro and in vivo in mice
Orasanu, G; Ziouzenkova, O; Devchand, PR; Nehra, V; Hamdy, O; Horton, ES; Plutzky, J
Journal of the American College of Cardiology, 52(): 869-881.
10.1016/j.jacc.2008.04.055
CrossRef
Current Opinion in Pharmacology
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy
Chinetti-Gbaguidi, G; Fruchart, JC; Staels, B
Current Opinion in Pharmacology, 5(2): 177-183.
10.1016/j.coph.2004.11.004
CrossRef
Current Pharmaceutical Design
Fibrate-associated adverse effects beyond muscle and liver toxicity
Florentin, M; Liberopoulos, EN; Mikhailidis, DP; Elisaf, MS
Current Pharmaceutical Design, 14(6): 574-587.

Current Pharmaceutical Design
Pleiotropic Effects of Fenofibrate
Tsimihodimos, V; Liberopoulos, E; Elisaf, M
Current Pharmaceutical Design, 15(5): 517-528.

Clinical Endocrinology
Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence
Preiss, D; Sattar, N
Clinical Endocrinology, 70(6): 815-828.
10.1111/j.1365-2265.2008.03490.x
CrossRef
Arteriosclerosis Thrombosis and Vascular Biology
Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate
Taskinen, MR; Sullivan, DR; Ehnholm, C; Whiting, M; Zannino, D; Simes, RJ; Keech, AC; Barter, PJ
Arteriosclerosis Thrombosis and Vascular Biology, 29(6): 950-U436.
10.1161/ATVBAHA.108.178228
CrossRef
Cardiovascular Drugs and Therapy
A Clinical Puzzle: Fibrates and Homocysteine Elevation
Davidson, MH
Cardiovascular Drugs and Therapy, 23(5): 341-342.
10.1007/s10557-009-6201-8
CrossRef
Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids
Safety issues and prospects for future generations of PPAR modulators
Rubenstrunk, A; Hanf, R; Hum, DW; Fruchart, JC; Staels, B
Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids, 1771(8): 1065-1081.
10.1016/j.bbalip.2007.02.003
CrossRef
American Journal of Kidney Diseases
Effect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people
Ansquer, JC; Dalton, RN; Causse, E; Crimet, D; Le Malicot, K; Foucher, C
American Journal of Kidney Diseases, 51(6): 904-913.
10.1053/j.ajkd.2008.01.014
CrossRef
Back to Top | Article Outline
Keywords:

fibrate; homocysteine; PPAR

© 2004 Lippincott Williams & Wilkins, Inc.

Follow Us!

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.